Assessment of Hepatitis C management on glycemic control among Type 2 Diabetes Mellitus patients | ||||
| Egyptian Journal of Chemistry | ||||
| Article 52, Volume 65, Issue 7, July 2022, Page 525-532 PDF (240.38 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejchem.2021.106210.4886 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Abdelrahman Hassanein   1; Moustafa Hassan Ragab2; Hanan Amer3; Dalia Elmosalami1; Mohamed Abdelrahman4; Thanaa Rabah5; Ahmed AboulGhate1; Hazem El-Hariri5
| ||||
| 1Community Medicine, National Research Center, Cairo, Egypt | ||||
| 2Faculty of Graduate studies and Environmental Research, Ain Shams University, Cairo, Egypt | ||||
| 3Endocrinology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt | ||||
| 4Community Medicine Department, National Research Center, Cairo, Egypt | ||||
| 5Community Medicine department, National Research Center, Cairo, Egypt | ||||
| Abstract | ||||
| Background: HCV and DM are chronic diseases of high global prevalence. Many studies proved the association between Hepatitis C and DM in the last three decades and this consists of an interrelated association; moreover, HCV infection triggers Diabetes Mellitus, most probably type 2. Objective: To assess the possibility of the improvement of T2DM in patients with HCV when applying the new DAA HCV treatment in Egypt. Patients and Methods: The current study is a prospective cohort hospital-based study that aims to describe the association between T2DM on one hand and chronic HCV on the other hand after successful management of HCV through the DAAs according to the protocol of the Ministry of Health. SVR was defined as undetectable HCV RNA levels at 12 weeks after the end of treatment (EOT). Fasting plasma glucose (FPG) levels between 100–125 mg/dL were defined as prediabetes and FPG ≥ 126 mg/dL was defined as diabetes. We have found positive correlation between management of HCV using DAAs in general and improvement of HbA1c and FPG. Moreover, we reported stronger correlation between achieving SVR and the HbA1c level and FPG. Results: After 12 weeks of follow-up, 82% of the patients maintained negative SVR, hemoglobin reduction was -0.6±0.4 %, 3 months after HCV treatment with a P value | ||||
| Keywords | ||||
| Diabetes Mellitus; HbA1c FPG FBG; glycemic control; HCV eradication; Egyptian patients; DAA; SVR | ||||
|
Statistics Article View: 183 PDF Download: 95 |
||||
